Last week, StemCells Inc. (Nasdaq: STEM) announced that transplanting its proprietary human neural stem cells into patients with retinal degeneration can prevent the loss of vision. Shares of the biotechnology company leaped 74 cents to $2.18.
StemCells Announces Positive Trial Results
November 03, 2008 at 11:42 AM EST
